Cost regulators for NHS treatments in England and Wales have deemed AbbVie’s Humira and Allergan’s Ozurdex clinically and cost effective for treating adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids.
Read More
Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss.
Read More
The FDA has approved AbbVie’s Humira for the treatment of non-infectious intermediate, posterior and panuveitis, marking its 10th green light in the country for an immune-mediated disease
Read More
